A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study of infliximab (Remicade) in subjects with Crohn's disease

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Men and women >=18 years of age

• Diagnosis of Crohn's

• Crohn's disease of at least 3 months duration, with colitis, ileitis, or ileocolitis, confirmed by radiography or endoscopy

Exclusion Criteria:

• Local manifestations of Crohn's disease such as strictures, abscesses, or other disease

• Surgery for bowel diversion with placement of a stoma within 3 months prior to beginning the study

• Positive stool culture